BNTX logo

BioNTech SE

BNTX
Healthcare|Biotechnology|DE
$87.51
+1.65 (+1.92%)
DCF Value
$46.34
Tangible Book / Share
$64.71
Cash / Share
$58.79

Financials

Financial Snapshot

Market Cap
$21.70B
Enterprise Value
$9.56B
Revenue (TTM)
$2.41B
Net Income (TTM)
-$1.48B
Cash & Investments
$10.20B
Net Cash
$9.84B
Free Cash Flow (TTM)
-$456.2M
Operating CF (TTM)
-$247.6M
Debt/Equity
0.02

Cash Runway & Burn Rate

Cash on Hand
$10.20B
Quarterly Burn
$61.9M
Monthly Burn
$20.6M
Est. Runway
~164.8 quarters
MetricTrend201720182019202020212022202320242025TTM
Cash & Investments
$172.4M$411.8M$520.8M$1.35B$2.07B$14.06B$16.55B$16.78B$14.83B$10.20B
Operating Cash Flow
-$52.6M-$58.2M-$198.5M-$13.5M$889.7M$13.58B$5.37B$207.7M$438.0M-$247.6M
Free Cash Flow
-$110.3M-$126.0M-$269.6M-$98.9M$735.7M$13.21B$4.67B-$244.6M$269.8M-$456.2M
Capital Expenditure
-$57.7M-$67.9M-$71.1M-$85.4M-$154.0M-$363.3M-$705.5M-$452.3M-$168.2M-$208.6M
Financing Cash Flow
-$1.6M$365.2M$383.3M$894.7M$94.2M-$1.42B-$778.6M-$45.9M-$50.8M-$330.7M

R&D Spending

R&D (TTM)
$2.37B
R&D Intensity
98.0%
R&D Growth vs Prior
+17.0%
MetricTrend201720182019202020212022202320242025TTM
Revenue
$61.6M$127.6M$108.6M$482.3M$18.98B$17.31B$3.82B$2.75B$2.76B$2.41B
R&D Expense
$85.5M$143.1M$226.5M$645.0M$949.2M$1.54B$1.78B$2.25B$2.02B$2.37B
R&D % of Revenue
138.8%112.1%208.6%133.7%5.0%8.9%46.7%81.9%73.3%98.0%
SG&A
$29.5M$27.1M$43.3M$108.5M$327.2M$541.2M$557.7M$599.0M$698.2M$818.8M

Income Statement

MetricTrend201720182019202020212022202320242025TTM
Revenue
$61.6M$127.6M$108.6M$482.3M$18.98B$17.31B$3.82B$2.75B$2.76B$2.41B
Cost of Revenue
$9.3M$13.7M$17.4M$59.3M$2.91B$3.00B$599.8M$541.3M$616.5M$726.3M
Gross Profit
$52.3M$113.9M$91.2M$423.0M$16.07B$14.32B$3.22B$2.21B$2.14B$1.69B
R&D
$85.5M$143.1M$226.5M$645.0M$949.2M$1.54B$1.78B$2.25B$2.02B$2.37B
SG&A
$29.5M$27.1M$43.3M$108.5M$327.2M$541.2M$557.7M$599.0M$698.2M$818.8M
Operating Income
-$61.3M-$53.9M-$181.5M-$82.4M$15.28B$12.64B$690.4M-$1.31B-$623.9M-$1.73B
Interest Expense
$651.4K$1.8M$1.7M$1.9M$5.6M$15.8M$7.8M$13.2M$13.6M$26.7M
Pretax Income
-$85.9M-$47.7M-$179.4M-$145.8M$15.05B$12.95B$1.19B-$677.7M-$1.01B-$1.44B
Net Income
-$85.7M-$48.0M-$179.1M$15.2M$10.29B$9.43B$930.3M-$665.3M-$1.09B-$1.48B
EPS (Diluted)
-0.38-0.21-0.850.0641.2137.093.83-2.77-4.51-5.88
EBITDA
-$74.7M-$24.0M-$143.8M-$105.1M$15.00B$13.10B$1.38B-$367.1M-$628.0M-$527.8M
Shares Out. (M)
226.86226.86211.50248.53259.70249.80242.70240.40241.70253.00

Balance Sheet

MetricTrend201720182019202020212022202320242025TTM
Cash & Equivalents
$172.1M$411.5M$519.1M$1.21B$1.69B$13.88B$11.66B$9.76B$7.67B$10.20B
Short-Term Investments
$246.0K$336.0K$1.7M$137.2M$381.6M$189.4M$4.89B$7.02B$7.16B$0.00
Total Current Assets
$189.6M$449.0M$560.2M$1.67B$15.07B$21.92B$19.53B$18.80B$16.14B$15.67B
Total Assets
$374.7M$653.0M$797.6M$2.32B$15.83B$23.28B$23.01B$22.53B$21.98B$20.17B
Total Current Liabilities
$158.5M$126.1M$138.1M$606.0M$3.48B$2.95B$2.07B$2.52B$2.14B$1.83B
Long-Term Debt
$0.00$0.00$14.8M$152.9M$171.6M$176.2M$191.0M$214.7M$29.9M$0.00
Total Liabilities
$422.9M$386.0M$304.2M$946.8M$3.94B$3.22B$2.76B$3.12B$2.76B$2.46B
Stockholders' Equity
-$49.3M$266.2M$493.5M$1.37B$11.89B$20.06B$20.25B$19.41B$19.22B$17.71B
Retained Earnings
-$197.8M-$245.8M-$424.8M-$409.6M$9.88B$18.83B$19.76B$19.10B$17.95B$16.79B

Cash Flow Statement

MetricTrend201720182019202020212022202320242025TTM
Operating Cash Flow
-$52.6M-$58.2M-$198.5M-$13.5M$889.7M$13.58B$5.37B$207.7M$438.0M-$247.6M
Capital Expenditure
-$57.7M-$67.9M-$71.1M-$85.4M-$154.0M-$363.3M-$705.5M-$452.3M-$168.2M-$208.6M
Free Cash Flow
-$110.3M-$126.0M-$269.6M-$98.9M$735.7M$13.21B$4.67B-$244.6M$269.8M-$456.2M
Investing Cash Flow
-$52.5M-$67.1M-$77.2M-$144.8M-$566.1M-$35.3M-$6.95B-$2.08B-$2.37B$771.3M
Financing Cash Flow
-$1.6M$365.2M$383.3M$894.7M$94.2M-$1.42B-$778.6M-$45.9M-$50.8M-$330.7M
Issuance of Stock
$0.00$361.7M$375.4M$753.0M$160.9M$110.5M$0.00$0.00$0.00$0.00
Repurchase of Stock
$0.00$0.00$0.00$0.00$0.00-$986.4M-$738.5M$0.00$0.00-$406.4M
Net Debt Issuance
-$1.6M$3.5M$7.9M$141.7M-$66.7M-$59.1M-$40.1M-$45.9M-$10.9M$111.4M
Stock Based Comp.
$5.9M$7.6M$30.2M$32.1M$93.9M$108.6M$51.4M$100.9M$0.00$20.0M
Net Change in Cash
-$131.6M$239.4M$107.6M$691.1M$482.5M$12.18B-$2.21B-$1.90B-$931.2M-$119.1M

Dilution Tracker

Shares Outstanding
248M
5-Year Share Growth
-2.7%
Stock Issuance (TTM)
$0.00
MetricTrend201720182019202020212022202320242025TTM
Shares Out. (M)
226.86226.86211.50248.53259.70249.80242.70240.40241.70253.00
Change vs Prior %
—0.0%-6.8%17.5%4.5%-3.8%-2.8%-0.9%0.5%4.7%
Stock Issuance
$0.00$361.7M$375.4M$753.0M$160.9M$110.5M$0.00$0.00$0.00$0.00
Stock Repurchase
$0.00$0.00$0.00$0.00$0.00-$986.4M-$738.5M$0.00$0.00-$406.4M
Stock Based Comp.
$5.9M$7.6M$30.2M$32.1M$93.9M$108.6M$51.4M$100.9M$0.00$20.0M

Margins & Profitability

MetricTrend201720182019202020212022202320242025TTM
Gross Margin %
84.9%89.3%84.0%87.7%84.7%82.7%84.3%80.3%77.6%69.9%
Operating Margin %
-99.5%-42.2%-167.1%-17.1%80.5%73.0%18.1%-47.8%-22.6%-71.5%
Net Margin %
-139.1%-37.6%-164.9%3.2%54.2%54.5%24.4%-24.2%-39.6%-61.3%
EBITDA Margin %
-121.3%-18.8%-132.4%-21.8%79.1%75.7%36.1%-13.3%-22.8%-21.9%
FCF Margin %
-179.1%-98.8%-248.3%-20.5%3.9%76.3%122.2%-8.9%9.8%-18.9%
ROE %
173.8%-18.0%-36.3%1.1%86.5%47.0%4.6%-3.4%-5.7%-8.1%
ROA %
-22.9%-7.4%-22.5%0.7%65.0%40.5%4.0%-3.0%-5.0%-7.4%
ROIC %
-28.3%-10.2%-27.3%0.5%83.8%45.2%2.6%-6.4%-3.1%-8.3%
R&D / Revenue %
138.8%112.1%208.6%133.7%5.0%8.9%46.7%81.9%73.3%98.0%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
0.0%0.0%107.1%-14.9%344.1%3834.6%-8.8%-77.9%-28.0%0.2%
Gross Profit
0.0%0.0%117.8%-19.9%363.8%3697.9%-10.9%-77.5%-31.4%-3.2%
Operating Income
0.0%0.0%12.1%-237.0%54.6%18648.3%-17.3%-94.5%-290.4%52.5%
Net Income
0.0%0.0%43.9%-273.0%108.5%67613.8%-8.3%-90.1%-171.5%-64.0%
EPS (Diluted)
0.0%0.0%44.7%-304.8%106.7%72198.2%-10.0%-89.7%-172.3%-62.8%
Operating Cash Flow
0.0%0.0%-10.7%-241.2%93.2%6690.4%1426.1%-60.4%-96.1%110.9%
Free Cash Flow
0.0%0.0%-14.3%-113.9%63.3%843.9%1696.1%-64.7%-105.2%210.3%
R&D Expense
0.0%0.0%67.3%58.3%184.8%47.2%61.9%16.0%26.4%-10.3%
SG&A Expense
0.0%0.0%-8.2%60.0%150.6%201.6%65.4%3.0%7.4%16.6%
Total Assets
0.0%-3.9%74.3%22.2%190.7%582.8%47.0%-1.2%-2.1%-2.4%
Book Value / Share
0.0%0.0%653.9%98.3%149.7%736.6%69.1%2.1%-4.0%-1.5%
Debt
0.0%88.8%7.7%36.9%223.5%25.6%-29.6%3.3%16.0%5.1%
Diluted Shares
0.0%0.0%0.0%-6.8%17.5%4.5%-3.8%-2.8%-0.9%0.5%

Valuation

P/E (TTM)At Loss
10Y Low / Med / High3.68 / 24.67 / 1107.97
P/S8.04
10Y Low / Med / High1.97 / 9.62 / 58.84
P/B1.10
10Y Low / Med / High1.02 / 4.65 / 12.95
EV/EBITDAAt Loss
10Y Low / Med / High1.56 / 3.59 / 8.37
EV/Revenue3.96
10Y Low / Med / High1.18 / 6.16 / 54.74
P/FCFAt Loss
10Y Low / Med / High2.58 / 72.58 / 75.19

Intrinsic Value Models (per share)

DCF Value
$46.34
Tangible Book / Share
$64.71
Net Current Assets / Share
$53.29
Graham Net-Net
$51.44
Cash / Share
$58.79
MetricTrend201720182019202020212022202320242025TTM
P/E Ratio
-31.22-59.13-35.541107.975.173.6824.67-39.73-17.97-13.29
P/S Ratio
43.6922.0858.8432.562.911.976.029.627.108.04
P/B Ratio
-54.5910.5812.9511.454.651.701.131.361.021.10
EV/EBITDA
-34.39-102.67-41.34-140.193.591.568.37-46.16-19.39-22.34
EV/Revenue
41.7119.2854.7430.552.841.183.026.164.423.96

Analyst Estimates & Quality

Altman Z-Score
6.62
Safe
Piotroski F-Score
4
Moderate

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$1.87B$1.87B$2.30B
Net Income-$1.39B-$1.37B-$911.7M
EPS$-5.74$-5.65$-4.59
# Analysts (EPS)6910

Dividends

Frequency
Irregular

Recent Payments

Ex-DatePay DateAmountFrequency
Jun 2, 2022Jun 17, 2022$2.11Irregular

Revenue Segments

By Product

Segment202020212022202320242025
Other Sales Transactions$33.0M—————
Commercial—$71.38B—$3.82B——
Research And Development—$205.4M$116.0M$3.5M——
Other Sales————$319.0M$261.6M

By Geography

Segment202020212022202320242025
GERMANY$20.6M$2.24B—$482.7M$706.9M$759.1M
UNITED STATES—$14.64B$12.71B$3.01B$1.85B$1.79B
DELAWARE——$3.03B———
Rest of the World————$196.4M$11.1M
IRELAND—————$304.8M